This is the authors' abstract. We don't add key points for this paper.
Background: Buprenorphine is usually administered to manage opioid use disorder and pain syndromes. It could be a proper treatment option for suicidality, resistant depression, self-destructive behavior, and anxiety. Buprenorphine has a considerable abuse potential that confines its administration in patients committing suicide with a background of substance abuse. Objectives: The current study aimed to clarify the influence of different doses of buprenorphine on opioid-dependent patients committing suicide over a 2-day period in a randomized, clinical trial (RCT). Patients and Methods: Patients were randomly assigned into 3 groups. Twenty-three suicidal male patients who met the DSM-5 (diagnostic and statistical manual of mental disorders) criteria for opioid dependence and sought treatment were recruited. Patients randomly received 32, 64, or 96 mg of buprenorphine as a single high-dose only and were hospitalized in a psychiatric inpatient ward. Out of the 23 patients, 9 (39.2%), 8 (34.8%), and 6 (26%) received 32, 64, and 96 mg of buprenorphine, respectively. Psychometric assessment was performed using the Beck scale for suicidal ideation (BSSI) and interview. All patients completed the 2-day treatment period. The results indicated a significant decrease in BSSI scores in each of the 3 groups (P < 0.05), but there was no difference in the outcome between the groups (P = 0.30). Conclusions: The current study results indicated that a single high-dose of buprenorphine could provide a speedy and safe means to treat suicidality in opioid-dependent patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ahmadi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: